Coeptis Therapeutics Holdings, Inc. announced it has entered into a binding term sheet with Deverra Therapeutics, Inc. (“Deverra Therapeutics”) pursuant to which it has obtained an exclusive right, until August 31, 2023.
Palatin Technologies, Inc. today announced The International Journal of Molecular Sciences published a manuscript, “Stimulating the Melanocortin System in Uveitis and Diabetes Preserves the Structure and Anti-Inflammatory Activity of the Retina” by Tat Fong Ng and Andrew W. Taylor from Department of Ophthalmology, Boston University Chobanian and Avedisian School of Medicine, in Boston, Massachusetts.
Ampio Pharmaceuticals, Inc. released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
Ampio Pharmaceuticals Issues Letter to Stockholders – April 18, 2023 Read More »
Ondine Biomedical Inc. presented detailed results from its US Phase 2 BENEFIT-aPDT clinical trial to the 33rd European Congress of Clinical Microbiology and Infectious Diseases in Copenhagen, Denmark.
Ondine Biomedical’s Nasal Photodisinfection Cuts Surgical Site Infections by 66% Read More »
Nordic Nanovector ASA announces that full results from its Phase 2 clinical trials of Betalutin® in resistant/refractory indolent non-Hodgkin’s lymphoma have been published at EudraCT, the European Union Drug Regulating Authorities Clinical Trials Database of the European Union.
Algunos de los asteroides que Lucy visitará se encuentran aún a más de 530 millones de kilómetros de la nave espacial, lo que supone más del triple de la distancia media entre la Tierra y el Sol. Pero a pesar de la gran distancia y de los tamaños peque&ntild …
La sonda espacial Lucy observa de lejos asteroides que visitará Read More »
El helicóptero robótico Ingenuity de la NASA ha efectuado su vuelo número 50 en Marte. El Ingenuity, que es la primera aeronave en volar en otro mundo, realizó ese vuelo número 50 el 13 de abril, recorriendo más de 322,2 metros en 145,7 segundos. El …
Biophytis SA announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting.
Biophytis: Results of the Combined General Meeting on April 17, 2023 Read More »
Biophytis SA announces its financial results for the year ended December 31, 2022, and provides updates on key perspectives for 2023.
Biophytis Announces 2022 Financial Results and 2023 Perspectives Read More »
AbbVie announced that the U.S. Food and Drug Administration has approved expanding the indication of QULIPTA® for the preventive treatment of migraine in adults.
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine Read More »
